

IBA Lifesciences GmbH Rudolf-Wissell-Str. 28 37079 Goettingen Germany Tel.: +49 (0) 551-5 06 72-0 E-mail: info@iba-lifesciences.com www.iba-lifesciences.com

Data Sheet

pDSG-IBA103

Cat. No.: 5-5220-001

Version: 3.0 Revision Date: 28.07.2021

Description	StarGate Acceptor Vector is a small transient expression vector especially developed for the use in combination with the MEXi mammalian expression system. In addition, it contains the human cytomegalovirus (CMV) immediate-early promoter for high-level expression and the origin of replication from Epstein-Barr Virus (oriP) for extrachromosomal replication driven by EBNA-1 expressed by MEXi-293E cells. The expressed recombinant protein will be localized in the cytoplasm.			
Affinity tag	Twin-Strep-tag [®] is fused to the C-terminus of the recombinant protein.			
Cloning Strategy	Cloning into StarGate Acceptor Vectors has to be done with the restriction enzyme Esp3I. There is no Multiple Cloning Site (MCS) available that can be used for the integration of the gene of interest instead (see manual).			
Resistance	Ampicillin: for selection of transformed E. coli cells			
Form	5 μg, dissolved in 20 μl TE buffer, pH 8.0: 10 mM Tris/HCl, 1 mM EDTA			
Concentration	250 ng/μl			
Stability	12 months after shipping			
Storage	recommended: 2-8 °C for frequent usage, -20 °C for long-term storage			
Shipping	room temperature			
Hazards	Product is not classified as hazardous according to (EC) No 1272/2008 [CLP]. A Material Safety Data Sheet is provided.			

For research use only


Trademark information


The owners of trademarks marked by "®" or "TM" are identified at <u>http://www.iba-lifesciences.com/patents.html</u>. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

Important licensing information

This product is covered by intellectual property (IP) rights and on completion of the sale IBA Lifesciences grants respective Limited Use Label Licenses to purchaser. IP rights and Limited Use Label Licenses for said technology are further described and identified at http://www.iba-lifesciences.com/patents.html or upon inquiry at info@iba-lifesciences.com/patents.html or upon inquiry at info@iba-lifesciences.com or at IBA Lifesciences GmbH, Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany. By use of this product the purchaser accepts the terms and conditions of all applicable Limited Use Label Licenses.

Expression cassette of pDSG-IBA103





 $\label{eq:LacP/Z cassette} \begin{array}{l} \mbox{contains LacZ alpha fragment under control} \\ \mbox{of a separate promoter, which allows alpha} \\ \mbox{complementation of } LacZ mutations such as \\ LacZ\Delta M15 \mbox{ as in } E. \mbox{ coli} DH5\alpha \mbox{ or TOP10.} \\ \mbox{after StarGate cloning using } Esp3l \mbox{ your gene} \\ \mbox{of interest will be located here} \end{array}$

Features	from bp	to bp	Sequencing primer
polyA signal sequence	1	213	ESG/CSG-Primer-for
pUC ori origin	222	836	
Ampicillin resistance gene	999	1856	5'- GAGAACCCACTGCTTACTGGC -3'
oriP, episomal replication origin	2021	3996	
CMV promoter	4277	4864	
forward primer binding site	4877	4897	ESG/CSG-Primer-rev
LacZ alpha fragment	5168	5569	5'- TAGAAGGCACAGTCGAGG -3'
Twin-Strep-tag [®]	5633	5725	
reverse primer binding site	5787	5804	
total vector length		5804	